BriaCell Therapeutics Corp. BCTX
BriaCell Therapeutics Corp. (Nasdaq: BCTX) is an oncology drug developer. Its lead program, Bria-IMT (SV-BR-1-GM) plus checkpoint inhibitor, is in Phase 3 for advanced metastatic breast cancer (pivotal Phase 3, Bria-ABC, NCT06072612). Its next catalyst on record is Bria-BRES+: Initiate Phase 1/2a study in metastatic breast cancer (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Bria-BRES+ — Initiate Phase 1/2a study in metastatic breast cancer (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Bria-IMT + retifanlimab | metastatic breast cancer (pivotal Phase 3, Fast Track) | cell therapy | Phase 3 |
| Bria-OTS (Bria-BRES) | metastatic breast cancer (Phase 1/2a, now combination with checkpoint inhibitor) | cell therapy | Phase 1 |
| Bria-BRES+ | metastatic breast cancer (IND cleared May 2026; Phase 1/2a planned) | cell therapy | Pre-clinical |
| Bria-PROS+ | prostate cancer (clinical supplies manufactured; pre-IND meeting positive) | cell therapy | Pre-clinical |
| Bria-OVA+ | ovarian cancer | cell therapy | Pre-clinical |
| BriaPro TILsRx / B7-H3 antibodies and sCD80 | solid tumors (via majority-owned BriaPro) | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.